Immunogenicity and Safety of Hepatitis A Vaccine in Children With Chronic Liver Disease
作者:
Cristina Ferreira,
Themis da Silveira,
Sandra Maria Vieira,
Adriano Taniguchi,
Jorge Pereira-Lima,
期刊:
Journal of Pediatric Gastroenterology and Nutrition
(OVID Available online 2003)
卷期:
Volume 37,
issue 3
页码: 258-261
ISSN:0277-2116
年代: 2003
出版商: OVID
关键词: Hepatitis A virus;Hepatitis A vaccine;Immunization;Geometric mean titers;Cirrhosis;Chronic liver disease children
数据来源: OVID
摘要:
BackgroundAcute hepatitis A superimposed on chronic liver disease has been associated with a more severe course of disease and development of fulminant hepatitis. The aim of this study was to evaluate the immunogenicity and safety of an inactivated hepatitis A virus vaccine in children with chronic liver disease.Patients and MethodsThis was an open, prospective, and controlled trial with 89 anti-HAV negative children between 1 and 16 years of age studied at a pediatric liver disease and transplantation referral center. Inactivated HAV vaccine (Havrix), from GlaxoSmithKline Biologicals containing 720 Elisa units of alum-adsorbed hepatitis A antigen per 0.5 ml dose was used. Thirty-four pediatric patients with chronic liver disease (mean age: 7.0 ± 4.86 years) and 55 healthy controls (mean age: 4.8 ± 2.7 years) received two doses of Havrix vaccine in months zero and six. Seroconversion and anti-HAV titers expressed as geometric mean titers (GMT) in mIU/ml were measured at months one and seven, by a modified Hepatitis A virus andibodies (HAVAB) assay.ResultsSeroconversion rates at four weeks after primary immunization were 76% and 94% and the GMT 107.77 and 160.77 mIU/ml in the patient and control groups, respectively. One month after second dose the seroconversion rates were 97% and 100% in the groups with GMT of 812.40 and 2344.90 mIU/ml. Both doses were well tolerated with no significant adverse events observed. Local injection-site symptoms were the most common reactions reported in both groups.ConclusionAlthough GMTs were significantly lower in children with chronic liver disease compared to healthy controls, the overall seroconversion rates were not different. Hepatitis A virus vaccine was safe, well-tolerated, and immunogenic in children with chronic liver disease.
点击下载:
PDF
(197KB)
返 回